Land: Kanada
Sprache: Englisch
Quelle: Health Canada
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE)
NOVARTIS PHARMACEUTICALS CANADA INC
S03AA07
CIPROFLOXACIN
0.3%
SOLUTION
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 0.3%
OPHTHALMIC
5ML/10ML
Prescription
ANTIBACTERIALS
Active ingredient group (AIG) number: 0123207004; AHFS:
APPROVED
2017-04-03
_CILOXAN_ _®_ _ Product Monograph _ _ _ 1 _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr CILOXAN ® Ciprofloxacin Ophthalmic Solution, USP 0.3% w/v (as ciprofloxacin hydrochloride) Antibacterial Agent and Pr CILOXAN ® Ciprofloxacin Ophthalmic Ointment, USP 0.3% w/w (as ciprofloxacin hydrochloride) Antibacterial Agent Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec H9S 1A9 Date of Revision: www.novartis.ca May 22, 2018 Submission Control No.: 210590 CILOXAN and DROP-TAINER are registered trademarks. _CILOXAN_ _®_ _ Product Monograph _ _ _ 2 _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................7 DRUG INTERACTIONS ....................................................................................................8 DOSAGE AND ADMINISTRATION ................................................................................8 ACTION AND CLINICAL PHARMACOLOGY ............................................................10 STORAGE AND STABILITY ..........................................................................................10 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................10 PART II: SCIENTIFIC INFORMATION ................................................................................11 DETAILED PHARMACOLOGY .....................................................................................11 MICROBIOLOGY............ Lesen Sie das vollständige Dokument